With the 44^th Annual JP Morgan Healthcare Conference less than a month away, the industry is preparing for major announcements from some of its biggest players.

Johnson & Johnson announced that management will hold a fireside chat at 11:15 am, Est, on Monday, January 12, 2026. It will also be presented as a live audio webcast on J&J’s investor relations site.

While the company is keeping details of its presentation under wraps, it has used previous conferences as an opportunity to announce major acquisitions.

2025 – J&J Acquires Intra-Cellular Therapies

In a statement covering the $14.6 billion acquisition,¹ J&J’s chairman and chief executive officer Joaquin Duato said, “Building on our nearly 70-year legacy in neuroscience, this unique opportunity to add Intra-Cellular Therapies to our Innovative Medicine business demonstrates our commitment to transforming care and advancing research in some of today’s most devastating neuropsychiatric and neurodegenerative disorders. This acquisition further differentiates our portfolio, serves as a strategic near- and long-term growth catalyst for Johnson & Johnson and offers compelling value to patients, health systems and shareholders.”

Jennifer Taubert, executive vice president and worldwide chairman of innovative medicine at J&J added, “We are excited to welcome Intra-Cellular Therapies’ talented people and world-class expertise to Johnson & Johnson. Together, we have an opportunity to impact even more patients living with neuropsychiatric and neurodegenerative disorders, significantly advancing care and helping improve the lives of millions worldwide.”

The sale closed in April 2025, at which point Intra-Cellular Therapies began operating as a business unit within J&J.

In a press release issued at the time,² chairman and CEO of Intra-Cellular Therapies Dr. Sharon Mates said, “CAPLYTA®’s success and the robust pipeline we have built demonstrates the passion and dedication of our talented team, and we are proud of the hundreds of thousands of patients we have helped. Johnson & Johnson has a longstanding commitment to neuroscience, and we believe together, we can reach even more patients around the world.”

2024 – J&J Acquires Ambrx

The deal, which brought the clinical stage biopharmaceutical company and its proprietary synthetic biology technology platform under J&J’s umbrella, totaled nearly $2 billion.³

In the announcement, global therapeutic area head of oncology at Johnson & Johnson Innovative Medicine Yusri Elsayed, MD, MHSc, PhD, said, “Ambrx’s ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities. The results seen to date with ARX517 in mCRPC are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease. In addition, Ambrx’s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of cancer and improve patients’ lives.”

Margaret Yu, MD, prostate cancer disease area leader at Johnson & Johnson, added, “With a median overall survival of less than two years and novel hormonal therapies moving earlier in the disease, significant unmet need remains in the treatment of mCRPC. We see a unique opportunity to harness the potential of this innovative ADC platform, and with our deep understanding of prostate cancer, deliver a targeted PSMA therapeutic for addressing the growing needs of the more than 185,000 patients living with metastatic castration-resistant disease today.”

Johnson & Johnson’s acquisition of Ambrx closed in March, 2024.

Sources

1. Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. Johnson and Johnson. January 13, 2025. Accessed December 12, 2025. https://www.jnj.com/media-center/press-releases/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-inc
2. Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership. Johnson and Johnson. April 2, 2025. Accessed December 12, 2025. https://www.jnj.com/media-center/press-releases/johnson-johnson-closes-landmark-intra-cellular-therapies-acquisition-to-solidify-neuroscience-leadership
3. Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer. Johnson and Johnson. January 8, 2024. Accessed December 12, 2025. https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-ambrx-advancing-next-generation-antibody-drug-conjugates-to-transform-the-treatment-of-cancer